TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12061670

Group type: EXPERIMENTAL
Intervention: Subcutaneous erythropoietin (600 U/kg per week) and oral iron (3 mg/kg per day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 27
Study: 9706280

Group type: EXPERIMENTAL
Intervention: Warfarin stroke prophylaxis
Number of subjects: 5
Study: 7619034

Group type: EXPERIMENTAL
Intervention: Whole body immersion to the neck in water at 40 degrees C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immersion of two hands plus forearms in water at 42 degrees C
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive rewarming
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immersion of arms in hot water during immersion to the neck in cold water
Number of subjects: 0
Study: 2696576

Group type: EXPERIMENTAL
Intervention: Capitation system of payment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fee-for-service remuneration system
Number of subjects: 0
Study: 339132

Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg/day for 2 months
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo for 2 weeks before and after indapamide
Number of subjects: 47
Study: 31078463

Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg orally twice daily and pembrolizumab 200 mg intravenously for 30 min on day 8 and every 3 weeks for cycles of 6 weeks for up to 2 years, followed by escalating doses of axitinib (2-10 mg) plus flat dose pembrolizumab.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events
Number of subjects: 33
Study: 28371702

Group type: EXPERIMENTAL
Intervention: High control over exposure (manipulated by joystick movement)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Low control over exposure (yoked with high control counterpart)
Number of subjects: 96
Study: 25932592

Group type: EXPERIMENTAL
Intervention: CAF + CTG
Number of subjects: 24

Group type: COMPARATOR
Intervention: CAF
Number of subjects: 24
Study: 23937766

Group type: EXPERIMENTAL
Intervention: Gold standard supervision strategies
Number of subjects: 390

Group type: COMPARATOR
Intervention: Usual supervision practices
Number of subjects: 390
Study: 21857330

Group type: EXPERIMENTAL
Intervention: Group physical activity intervention for 30 minutes three times a week for 16 weeks
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 77
Study: 18363201

Group type: EXPERIMENTAL
Intervention: Nebulized formoterol fumarate (FFIS 20 microg)
Number of subjects: 351

Group type: COMPARATOR
Intervention: DPI (Foradil Aerolizer; FA 12 microg)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study: 15763453

Group type: EXPERIMENTAL
Intervention: Formoterol 4.5 microg
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Formoterol 54 microg
Number of subjects: 1130

Group type: COMPARATOR
Intervention: Terbutaline 0.5 mg
Number of subjects: 1130

Group type: COMPARATOR
Intervention: Terbutaline 6 mg
Number of subjects: 1130
Study: 11871761

Group type: EXPERIMENTAL
Intervention: Propranolol (n = 10)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 19
Study: 10102971

Group type: EXPERIMENTAL
Intervention: Asacol (mesalazine) 1.2 g daily for 12 months in Group A (1-2 years remission)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo in Group A (1-2 years remission)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Asacol (mesalazine) 1.2 g daily for 12 months in Group B (over 2 years remission)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo in Group B (over 2 years remission)
Number of subjects: 112
Study: 8561490

Group type: EXPERIMENTAL
Intervention: Side-by-side condition
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: After-consumption condition
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Appropriateness ratings
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ad libitum consumption
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall consistency of hedonic responses
Number of subjects: 40
Study: 2294526

Group type: EXPERIMENTAL
Intervention: Biofeedback-facilitated exercise
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (nonfeedback) Group
Number of subjects: 22
Study: 429787

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine containing the recombinant of A/Victoria/3/75 with A/PR/8/34 virus
Number of subjects: 2115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2115
Study: 31590097

Group type: EXPERIMENTAL
Intervention: Recurrence plots (RP) features analysis from airflow (AF) recordings.
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: 3% oxygen desaturation index (ODI3).
Number of subjects: 946
Study: 30308538

Group type: EXPERIMENTAL
Intervention: Short (24 hours) antibiotic administration
Number of subjects: 80

Group type: COMPARATOR
Intervention: Extended (>24 hours) antibiotic administration
Number of subjects: 80
Study: 28231619

Group type: EXPERIMENTAL
Intervention: CAF + CTG
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: TUN + CTG
Number of subjects: 42

Group type: COMPARATOR
Intervention: Both approaches
Number of subjects: 42
Study: 25986294

Group type: EXPERIMENTAL
Intervention: Self-management support intervention delivered by registered nurses specialized in pain and palliative care.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (control group).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-management support intervention.
Number of subjects: 0
Study: 23225308

Group type: EXPERIMENTAL
Intervention: Diclofenac suppository-nabumetone combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nabumetone administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6-MNA (active metabolite of nabumetone)
Number of subjects: 0
Study: 21647699

Group type: EXPERIMENTAL
Intervention: Oxygen administration (5 l/min) during spontaneous breathing in diabetic participants
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Oxygen administration (5 l/min)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Slow breathing in normoxia
Number of subjects: 136
Study: 19520194

Group type: EXPERIMENTAL
Intervention: Resistance exercise program
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise program
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study: 16508743

Group type: EXPERIMENTAL
Intervention: Video laryngoscopy-guided application of cricoid pressure (group I)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Conventional, 'blind', application of cricoid pressure (group II)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Video laryngoscopy (VIL)
Number of subjects: 170
Study: 15987398

Group type: EXPERIMENTAL
Intervention: Air-cushioned mattress
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional foam mattress
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prone positioning (PP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both support types
Number of subjects: 20
Study: 12195197

Group type: EXPERIMENTAL
Intervention: Proximally based gluteus maximus flap
Number of subjects: 12

Group type: COMPARATOR
Intervention: Distally based gluteus maximus flap
Number of subjects: 12
Study: 10207809

Group type: EXPERIMENTAL
Intervention: Serum tumor markers CEA, CA 19-9, CA 50, CA 242
Number of subjects: 75
Study: 8538183

Group type: EXPERIMENTAL
Intervention: High-dose 13-cis-retinoic acid (13cRA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose followed by low-dose 13-cis-retinoic acid (13cRA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant high-dose 13-cis-retinoic acid (13cRA)
Number of subjects: 0
Study: 2142026

Group type: EXPERIMENTAL
Intervention: CGS 16949A 0.3 mg twice daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CGS 16949A 1.0 mg twice daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CGS 16949A 2.0 mg twice daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: CGS 16949A 0.1 mg twice daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CGS 16949A (all doses)
Number of subjects: 24
Study: 482183

Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31904404

Group type: EXPERIMENTAL
Intervention: Working memory training
Number of subjects: 42

Group type: COMPARATOR
Intervention: Active control treatment
Number of subjects: 42
Study: 30682704

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet)
Number of subjects: 65

Group type: COMPARATOR
Intervention: low-fat diet
Number of subjects: 65
Study: 27838569

Group type: EXPERIMENTAL
Intervention: Rheo Knee II (microprocessor-controlled prosthetic knee)
Number of subjects: 9

Group type: COMPARATOR
Intervention: NMPK (non-microprocessor-controlled prosthetic knee)
Number of subjects: 9
Study: 26347894

Group type: EXPERIMENTAL
Intervention: 12-week group-based lifestyle intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wait control
Number of subjects: 50
Study: 23558857

Group type: EXPERIMENTAL
Intervention: Attribution retraining group therapy (ARGT)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 129
Study: 21169287

Group type: EXPERIMENTAL
Intervention: PET-CT
Number of subjects: 189

Group type: COMPARATOR
Intervention: Conventional Work Up (CWU)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: PET-CT (excluding patients where PET-CT was not performed)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Conventional Work Up (CWU) (excluding patients where PET-CT was not performed)
Number of subjects: 189
Study: 19186960

Group type: EXPERIMENTAL
Intervention: Magnesium-enriched hydroxyapatite (MHA)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Calcium sulfate (CS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (unfilled sockets)
Number of subjects: 15
Study: 17162400

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 42
Study: 15389174

Group type: EXPERIMENTAL
Intervention: Manual therapy in addition to the stay-active concept
Number of subjects: 160

Group type: COMPARATOR
Intervention: Stay-active concept only (reference group)
Number of subjects: 160
Study: 11801963

Group type: EXPERIMENTAL
Intervention: p53+ status
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Ki-67+ status
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: p53-/Ki-67- status
Number of subjects: 105
Study: 9553435

Group type: EXPERIMENTAL
Intervention: Extracorporeal ultraviolet blood irradiation (EUVBR)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Extracorporeal ultraviolet blood irradiation (EUVBR) with antibiotic therapy
Number of subjects: 67
Study: 7851112

Group type: EXPERIMENTAL
Intervention: High-protection sunscreen
Number of subjects: 1626

Group type: EXPERIMENTAL
Intervention: Dietary supplementation with beta-carotene (30 mg daily)
Number of subjects: 1626

Group type: EXPERIMENTAL
Intervention: High-protection sunscreen and dietary supplementation with beta-carotene
Number of subjects: 1626
Study: 3187397

Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 151

Group type: COMPARATOR
Intervention: Orchiectomy
Number of subjects: 151
Study: 29319350

Group type: EXPERIMENTAL
Intervention: Extended-length plate
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard-length plate
Number of subjects: 16
Study: 29862620

Group type: EXPERIMENTAL
Intervention: Circadian alignment (nocturnal bedtime)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Circadian misalignment (12-hour inverted behavioural/environmental cycles)
Number of subjects: 14
Study: 26994091

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir (400/100 mg) with tenofovir disoproxil/emtricitabine (245/200 mg) once daily
Number of subjects: 237

Group type: COMPARATOR
Intervention: Maraviroc (300 mg) with tenofovir disoproxil/emtricitabine (245/200 mg) once daily
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 237
Study: 24656495

Group type: EXPERIMENTAL
Intervention: Calvarial bone dust (n=30, group I)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Calvarial bone and demineralized bone matrix (DBM; n=30, group II)
Number of subjects: 60
Study: 22396769

Group type: EXPERIMENTAL
Intervention: Taxane-anthracycline-capecitabine regimen
Number of subjects: 0
Study: 20388648

Group type: EXPERIMENTAL
Intervention: Plasma CgA levels at baseline
Number of subjects: 1233

Group type: COMPARATOR
Intervention: Randomized treatments with n-3 polyunsaturated fatty acid or rosuvastatin
Number of subjects: 1233
Study: 17684130

Group type: EXPERIMENTAL
Intervention: Smokeless tobacco users
Number of subjects: 602
Study: 15754239

Group type: EXPERIMENTAL
Intervention: Operative therapy (IVO)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Conservative therapy followed by operative intervention
Number of subjects: 66
Study: 11844964

Group type: EXPERIMENTAL
Intervention: Exosurf (artificial surfactant)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 22
Study: 10204832

Group type: COMPARATOR
Intervention: Medium or ultra-fine wheat bran with 10% energy as wheat gluten (1-month metabolic diet)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Coarse or a mixture of ultra-fine and coarse wheat bran (2-week ad libitum diet)
Number of subjects: 48
Study: 7772514

Group type: EXPERIMENTAL
Intervention: High-dose vincristine (4 mg/m2 over 4 d) combined with fractionated total body irradiation (F-TBI) (200 cGy x 2 over 3 d) and cyclophosphamide (60 mg/kg for 2 d) in AlloBMT
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High-dose vincristine (4 mg/m2 over 4 d) combined with fractionated total body irradiation (F-TBI) (200 cGy x 2 over 3 d) and cyclophosphamide (60 mg/kg for 2 d) in ABMT
Number of subjects: 75

Group type: COMPARATOR
Intervention: AlloBMT
Number of subjects: 75

Group type: COMPARATOR
Intervention: ABMT
Number of subjects: 75
Study: 2189452

Group type: EXPERIMENTAL
Intervention: Alfentanil 15 micrograms/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alfentanil 30 micrograms/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lidocaine 2 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline 10 ml
Number of subjects: 60
Study: 457017

Group type: EXPERIMENTAL
Intervention: 100 mg Allopurinol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20 mg Benzbromarone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of Allopurinol and Benzbromarone
Number of subjects: 12
Study: 30482651

Group type: EXPERIMENTAL
Intervention: Apical U-shape splitting technique
Number of subjects: 36

Group type: COMPARATOR
Intervention: Guided bone regeneration (GBR)
Number of subjects: 36
Study: 29405611

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 26840133

Group type: EXPERIMENTAL
Intervention: Metformin (3.0 g per day)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 24354519

Group type: EXPERIMENTAL
Intervention: Tissue kallikrein treatment (intravenous infusion of tissue kallikrein 0.15 PNAU/d for 7 days, followed by oral pancreatic kallikrein enteric-coated tablet 240 U, 3 times a day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no tissue kallikrein treatment)
Number of subjects: 90
Study: 22958295

Group type: EXPERIMENTAL
Intervention: 3 quality aspects of hospitals
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: 7 quality aspects of hospitals
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: 11 quality aspects of hospitals
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: 15 quality aspects of hospitals
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Consumer characteristics (especially age) and skills (especially literacy)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Active choice behaviour
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Amount of information
Number of subjects: 414
Study: 20980943

Group type: EXPERIMENTAL
Intervention: 600 mg intravenous N-acetylcysteine (NAC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No N-acetylcysteine (Control)
Number of subjects: 60
Study: 17320198

Group type: EXPERIMENTAL
Intervention: PACAP38 (10 pmol kg(‐1) min(‐1))
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PACAP38
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 12
Study: 16265685

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Quinapril (10 mg/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 11901039

Group type: EXPERIMENTAL
Intervention: Azithromycin for 5 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 5 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10978973

Group type: EXPERIMENTAL
Intervention: Balloon mitral valvuloplasty (BMV)
Number of subjects: 51
Study: 8994013

Group type: EXPERIMENTAL
Intervention: MCP UD (MUD) splint
Number of subjects: 26
Study: 1619103

Group type: EXPERIMENTAL
Intervention: Low-dose cranial radiation therapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: High-dose chemotherapy
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 49
Study: 6496209

Group type: EXPERIMENTAL
Intervention: Group monetary contracts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual monetary contracts
Number of subjects: 0
Study: 31617857

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support supplemented with Cognitive Remediation and Work-Focused Social Skills Training
Number of subjects: 0
Study: 29321686

Group type: EXPERIMENTAL
Intervention: Monitoring intervention group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Seasoning intervention group
Number of subjects: 50
Study: 27018995

Group type: EXPERIMENTAL
Intervention: LTOT + TA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LTOT + NIV + TA
Number of subjects: 0

Group type: COMPARATOR
Intervention: LTOT
Number of subjects: 0

Group type: COMPARATOR
Intervention: LTOT + NIV
Number of subjects: 0
Study: 25029210

Group type: EXPERIMENTAL
Intervention: Fr + G (13C‐labelled fructose, unlabeled glucose, lipids and protein)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fr (13C‐labelled fructose, lipids and protein)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Fr + G
Number of subjects: 8
Study: 23157043

Group type: EXPERIMENTAL
Intervention: 10 mg dinoprostone vaginal insert single dose
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 100
Study: 20517830

Group type: EXPERIMENTAL
Intervention: Clomifene + Metformin (Metformin 850 mg twice a day for 8 weeks, Clomifene 100 mg per day for 5 days)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Clomifene only (100 mg per day for 5 days)
Number of subjects: 63
Study: 18480685

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study: 16182989

Group type: EXPERIMENTAL
Intervention: Group 1 (physicians using Wood lamp)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Group 2 (physicians using Wood lamp)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Interrater agreement
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intrarater agreement for Group 1
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intrarater agreement for Group 2
Number of subjects: 150

Group type: COMPARATOR
Intervention: Prevalence of urine fluorescence
Number of subjects: 150
Study: 12527974

Group type: EXPERIMENTAL
Intervention: 6% CHO solution
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 12% CHO solution
Number of subjects: 14

Group type: COMPARATOR
Intervention: 0% CHO solution
Number of subjects: 14
Study: 10658884

Group type: EXPERIMENTAL
Intervention: 2-session stress management group
Number of subjects: 178

Group type: COMPARATOR
Intervention: usual-care control condition
Number of subjects: 178
Study: 8892196

Group type: EXPERIMENTAL
Intervention: CT scans
Number of subjects: 128

Group type: COMPARATOR
Intervention: Chest radiographs
Number of subjects: 128
Study: 1508061

Group type: EXPERIMENTAL
Intervention: Transdermal oestrogen (50 or 100 micrograms/24 h) combined with oral progestogen (5 mg medroxyprogesterone acetate for 14 days each cycle)
Number of subjects: 59
Study: 30768383

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Extended treatment with continued CBT or pharmacotherapy with sertraline
Number of subjects: 269
Study: 31492103

Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) infusion (20 IU insulin with 10 mEq KCL in 50 ml glucose 40%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) pretreatment after cardiopulmonary bypass
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (after cardiopulmonary bypass)
Number of subjects: 0
Study: 28196160

Group type: EXPERIMENTAL
Intervention: SRP + SMV (1.2 mg Simvastatin gel)
Number of subjects: 24

Group type: COMPARATOR
Intervention: SRP + placebo gel
Number of subjects: 24
Study: 26270952

Group type: EXPERIMENTAL
Intervention: Normalisation of SF by 3-weekly erythrocytapheresis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment with 3-weekly plasmapheresis (no normalisation of SF)
Number of subjects: 0
Study: 23568224

Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg for 4 days, coadministration with macitentan on day 5, continued for 19 additional days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Macitentan 10 mg single oral dose
Number of subjects: 10
Study: 20686810

Group type: EXPERIMENTAL
Intervention: frovatriptan 2.5 mg
Number of subjects: 148

Group type: COMPARATOR
Intervention: rizatriptan 10 mg
Number of subjects: 148